Pacello from the Institute Oncology of Renina in Italy comments on the results of the Phase II chlamydia study of perioperative chemoimmunotherapy in the study of EGFR.

Yes, we present the first results of the Chimera Phase II study.

The Chimera study is a Phase II clinical trial, a single-arm trial, enrolling patients with potentially resectable epithelioid or biphasic pleural mesothelioma.

Patients received three cycles of induction chemoimmunotherapy with platinum, pemetrex and pembrolizumab, followed by lung-sparing surgery and adjuvant pembrolizumab, up to 14 cycles.

The particular thing of this trial is that the surgical procedure was centralized at two high-volume centers, and the enrollment of the 41 patients were across eight Italian centers in 12 months.

So among the primary endpoint was the pathological complete response rate.

And among these 41 patients enrolled, 39 proceeded to surgery with a complete macroscopic resection rate of 95%.

She also provides our highlights on small cell lung cancer that were presented at this congress.